• Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

 

MISSION Therapeutics is a private drug discovery company focused on elucidating and targeting the ubiquitin pathway to treat cancers and other diseases. The company is developing small molecule drugs that target deubiquitylating enzymes (DUBs) involved in the DNA damage response, with the aim of inducing synthetic lethality, a powerful mechanism to selectively kill specific tumour cells. Our novel DUB technology platform integrates unique biology, screening and chemistry capabilities to rapidly and effectively select and develop compounds targeting DUBs.

View More
To deliver highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response.

MISSION is very saddened to hear of the untimely death of its great friend and colleague Dr Fritz Frickel.
We extend our condolences to his family at this difficult time.

News Updates


Apr 08, 2013
MISSION's Co-founder/CSO becomes Associate Faculty Member at the Wellcome Trust Sanger Institute

MISSION Co-Founder and CSO becomes an Associate Faculty Member at the Wellcome Trust Sanger Institute

more »



Feb 26, 2013
Biomedical Catalyst Feasibility award to tackle drug-resistant ovarian cancer

MISSION has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.
 

more »



 
 

DNA damage & the DNA damage response (DDR)
The DDR is required for cell survival. Several repair pathways cooperate and sometimes compete in response to different types of DNA damage, leading to the effective maintenance of genomic material in cells.
 

Synthetic lethality
The concept of synthetic lethality was first derived from genetic studies in model organisms, where mutation of a particular gene becomes lethal only through mutation or loss of another gene.
 

Ubiquitin processes in DDR
A wealth of scientific evidence shows that the post translational modification process of ubiquitylation and its reversal by deubiquitylation play key roles in regulating the DDR and associated processes.
 

Apr 08, 2013

MISSION Co-Founder and CSO becomes an Associate Faculty Member at the Wellcome Trust Sanger Institute

more »


Feb 26, 2013

MISSION has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.
 

more »


Dec 20, 2012

The MISSION Therapeutics team will be attending AACR 2013 in Washington DC (April 6-10 2013). Please contact us to arrange a meeting: enquiries@missiontherapeutics.com

more »


MISSION Therapeutics Ltd
Moneta (Building 280)
Babraham Research Campus
Cambridge
CB22 3AT


Twitter

Loading latest Tweets...

 
© 2013 MISSION Therapeutics, all rights reserved.
Website by College Hill Life Sciences